Concepts (176)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 15 | 2023 | 2796 | 1.520 |
Why?
|
| Epstein-Barr Virus Infections | 3 | 2023 | 489 | 1.110 |
Why?
|
| Cranial Irradiation | 2 | 2020 | 315 | 0.780 |
Why?
|
| Organ Transplantation | 1 | 2023 | 191 | 0.770 |
Why?
|
| Adult Survivors of Child Adverse Events | 1 | 2020 | 20 | 0.760 |
Why?
|
| Cancer Survivors | 5 | 2022 | 650 | 0.760 |
Why?
|
| Hematologic Diseases | 1 | 2021 | 242 | 0.710 |
Why?
|
| Obesity | 4 | 2020 | 2884 | 0.690 |
Why?
|
| Histocompatibility Antigens Class I | 2 | 2015 | 235 | 0.600 |
Why?
|
| Overweight | 2 | 2020 | 484 | 0.580 |
Why?
|
| Genetic Markers | 3 | 2015 | 974 | 0.550 |
Why?
|
| Survivors | 6 | 2020 | 1031 | 0.530 |
Why?
|
| Folic Acid | 3 | 2013 | 349 | 0.520 |
Why?
|
| Polymorphism, Single Nucleotide | 6 | 2020 | 4549 | 0.510 |
Why?
|
| Lymphoma | 1 | 2023 | 1467 | 0.500 |
Why?
|
| Lymphoproliferative Disorders | 2 | 2021 | 366 | 0.490 |
Why?
|
| Body Mass Index | 3 | 2020 | 2203 | 0.490 |
Why?
|
| Conscious Sedation | 1 | 2012 | 104 | 0.390 |
Why?
|
| Child | 29 | 2023 | 29154 | 0.390 |
Why?
|
| Hematology | 1 | 2012 | 104 | 0.370 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2011 | 336 | 0.340 |
Why?
|
| Polymorphism, Genetic | 2 | 2011 | 1450 | 0.330 |
Why?
|
| Membrane Proteins | 2 | 2015 | 2819 | 0.310 |
Why?
|
| Cancer Care Facilities | 1 | 2012 | 884 | 0.290 |
Why?
|
| Quality Assurance, Health Care | 1 | 2012 | 585 | 0.290 |
Why?
|
| Genotype | 5 | 2017 | 4109 | 0.290 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2015 | 5539 | 0.280 |
Why?
|
| Risk Factors | 11 | 2023 | 17523 | 0.280 |
Why?
|
| Evidence-Based Medicine | 1 | 2012 | 1085 | 0.280 |
Why?
|
| Cognition Disorders | 2 | 2011 | 786 | 0.270 |
Why?
|
| Postoperative Complications | 1 | 2020 | 5542 | 0.260 |
Why?
|
| Immunosuppressive Agents | 1 | 2011 | 1375 | 0.250 |
Why?
|
| Neoplasms | 7 | 2022 | 15193 | 0.250 |
Why?
|
| Quality Improvement | 1 | 2012 | 851 | 0.250 |
Why?
|
| Child, Preschool | 17 | 2021 | 16273 | 0.240 |
Why?
|
| Pediatrics | 2 | 2019 | 1141 | 0.240 |
Why?
|
| 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase | 2 | 2013 | 24 | 0.220 |
Why?
|
| Liver Transplantation | 1 | 2011 | 1112 | 0.210 |
Why?
|
| Methotrexate | 2 | 2023 | 999 | 0.210 |
Why?
|
| gamma-Glutamyl Hydrolase | 1 | 2021 | 12 | 0.200 |
Why?
|
| Pharyngitis | 1 | 2021 | 41 | 0.200 |
Why?
|
| Multidrug Resistance-Associated Proteins | 1 | 2021 | 83 | 0.190 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 2 | 2011 | 102 | 0.190 |
Why?
|
| DNA Methylation | 2 | 2020 | 2669 | 0.170 |
Why?
|
| Humans | 33 | 2023 | 261506 | 0.170 |
Why?
|
| Hemochromatosis Protein | 2 | 2015 | 23 | 0.170 |
Why?
|
| Adiposity | 1 | 2020 | 237 | 0.170 |
Why?
|
| Male | 22 | 2021 | 123000 | 0.170 |
Why?
|
| Francisella | 1 | 2017 | 1 | 0.160 |
Why?
|
| Tularemia | 1 | 2017 | 12 | 0.160 |
Why?
|
| Memory, Short-Term | 1 | 2019 | 160 | 0.160 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 1 | 2022 | 387 | 0.160 |
Why?
|
| Mycoses | 1 | 2021 | 386 | 0.150 |
Why?
|
| Genome-Wide Association Study | 3 | 2022 | 2265 | 0.150 |
Why?
|
| Attention | 1 | 2019 | 281 | 0.150 |
Why?
|
| Infant | 8 | 2021 | 13310 | 0.150 |
Why?
|
| Age Factors | 3 | 2021 | 5377 | 0.150 |
Why?
|
| Adolescent | 14 | 2021 | 31252 | 0.140 |
Why?
|
| Weight Gain | 1 | 2019 | 464 | 0.140 |
Why?
|
| Female | 22 | 2021 | 141928 | 0.130 |
Why?
|
| Aftercare | 1 | 2017 | 259 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 20 | 1 | 2015 | 64 | 0.130 |
Why?
|
| Iron-Regulatory Proteins | 1 | 2014 | 11 | 0.130 |
Why?
|
| Retrospective Studies | 7 | 2023 | 37905 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2015 | 135 | 0.120 |
Why?
|
| Health Services | 1 | 2014 | 105 | 0.120 |
Why?
|
| Positron-Emission Tomography | 2 | 2013 | 2173 | 0.120 |
Why?
|
| Diabetes Mellitus | 1 | 2022 | 1054 | 0.120 |
Why?
|
| Birth Weight | 1 | 2015 | 374 | 0.110 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2019 | 1039 | 0.110 |
Why?
|
| Case-Control Studies | 4 | 2015 | 6100 | 0.110 |
Why?
|
| Gene-Environment Interaction | 1 | 2013 | 166 | 0.110 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2017 | 573 | 0.100 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2015 | 301 | 0.100 |
Why?
|
| Pandemics | 1 | 2021 | 1559 | 0.100 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2022 | 1664 | 0.100 |
Why?
|
| Gestational Age | 1 | 2015 | 1069 | 0.100 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 1217 | 0.100 |
Why?
|
| Radiation Dosage | 2 | 2013 | 1014 | 0.100 |
Why?
|
| Burkitt Lymphoma | 1 | 2013 | 335 | 0.100 |
Why?
|
| Models, Genetic | 2 | 2014 | 1113 | 0.090 |
Why?
|
| Transplantation Conditioning | 1 | 2019 | 2238 | 0.090 |
Why?
|
| Premature Birth | 1 | 2015 | 407 | 0.090 |
Why?
|
| Texas | 1 | 2021 | 6311 | 0.090 |
Why?
|
| Early Diagnosis | 1 | 2011 | 298 | 0.090 |
Why?
|
| Hematologic Neoplasms | 1 | 2021 | 1870 | 0.090 |
Why?
|
| Young Adult | 4 | 2021 | 21445 | 0.090 |
Why?
|
| Cross-Sectional Studies | 2 | 2016 | 4314 | 0.090 |
Why?
|
| Antineoplastic Agents | 2 | 2011 | 14289 | 0.080 |
Why?
|
| Predictive Value of Tests | 3 | 2015 | 4892 | 0.080 |
Why?
|
| Prevalence | 1 | 2016 | 3260 | 0.080 |
Why?
|
| Infant, Newborn | 3 | 2017 | 8223 | 0.080 |
Why?
|
| Algorithms | 2 | 2021 | 3890 | 0.080 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2011 | 274 | 0.080 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2013 | 1226 | 0.080 |
Why?
|
| Chromosome Aberrations | 1 | 2015 | 1960 | 0.080 |
Why?
|
| Bayes Theorem | 2 | 2023 | 1021 | 0.080 |
Why?
|
| Herpesvirus 4, Human | 2 | 2022 | 966 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2013 | 7551 | 0.070 |
Why?
|
| Lymph Nodes | 1 | 2017 | 2967 | 0.070 |
Why?
|
| Adult | 6 | 2020 | 77950 | 0.070 |
Why?
|
| Lymphoma, B-Cell | 1 | 2013 | 895 | 0.070 |
Why?
|
| Prospective Studies | 1 | 2020 | 12873 | 0.070 |
Why?
|
| Hospitalization | 1 | 2014 | 2083 | 0.070 |
Why?
|
| Genetic Association Studies | 2 | 2021 | 1084 | 0.060 |
Why?
|
| Hodgkin Disease | 1 | 2012 | 1429 | 0.060 |
Why?
|
| Pregnancy | 1 | 2015 | 7573 | 0.050 |
Why?
|
| Cardiovascular Diseases | 2 | 2019 | 2195 | 0.050 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2019 | 6550 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 1 | 2012 | 2403 | 0.050 |
Why?
|
| Creatinine | 1 | 2023 | 531 | 0.050 |
Why?
|
| DNA Helicases | 1 | 2022 | 434 | 0.050 |
Why?
|
| Headache | 1 | 2021 | 163 | 0.050 |
Why?
|
| Ligands | 1 | 2022 | 995 | 0.040 |
Why?
|
| Medical Oncology | 1 | 2008 | 1423 | 0.040 |
Why?
|
| Autoimmunity | 1 | 2021 | 263 | 0.040 |
Why?
|
| Immunity | 1 | 2021 | 342 | 0.040 |
Why?
|
| Recurrence | 2 | 2019 | 4758 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2011 | 6869 | 0.040 |
Why?
|
| Photic Stimulation | 1 | 2019 | 259 | 0.040 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2022 | 661 | 0.040 |
Why?
|
| Treatment Outcome | 3 | 2019 | 32848 | 0.040 |
Why?
|
| Psychomotor Performance | 1 | 2019 | 233 | 0.040 |
Why?
|
| Residence Characteristics | 1 | 2020 | 348 | 0.040 |
Why?
|
| Fever | 1 | 2021 | 497 | 0.040 |
Why?
|
| Odds Ratio | 2 | 2014 | 2316 | 0.040 |
Why?
|
| Oxidoreductases | 1 | 2017 | 171 | 0.040 |
Why?
|
| Genes, Bacterial | 1 | 2017 | 236 | 0.040 |
Why?
|
| Genome, Bacterial | 1 | 2017 | 200 | 0.040 |
Why?
|
| Virulence Factors | 1 | 2017 | 213 | 0.030 |
Why?
|
| Whole Genome Sequencing | 1 | 2017 | 338 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2015 | 10331 | 0.030 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2022 | 1048 | 0.030 |
Why?
|
| DNA, Bacterial | 1 | 2017 | 558 | 0.030 |
Why?
|
| B7-H1 Antigen | 1 | 2022 | 1022 | 0.030 |
Why?
|
| Antifungal Agents | 1 | 2021 | 834 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2021 | 2927 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2013 | 10035 | 0.030 |
Why?
|
| Hospital Records | 1 | 2014 | 11 | 0.030 |
Why?
|
| Monosomy | 1 | 2015 | 95 | 0.030 |
Why?
|
| Neuropsychological Tests | 1 | 2019 | 1178 | 0.030 |
Why?
|
| Cognitive Dysfunction | 1 | 2019 | 333 | 0.030 |
Why?
|
| Transplantation, Homologous | 1 | 2019 | 2843 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2021 | 1589 | 0.030 |
Why?
|
| Patient Compliance | 1 | 2017 | 667 | 0.030 |
Why?
|
| Genetic Loci | 1 | 2014 | 481 | 0.030 |
Why?
|
| HLA Antigens | 1 | 2014 | 546 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2013 | 15862 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2014 | 1163 | 0.020 |
Why?
|
| Immunophenotyping | 1 | 2015 | 1681 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2017 | 2483 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 4298 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2015 | 2232 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2017 | 2086 | 0.020 |
Why?
|
| Dietary Supplements | 1 | 2013 | 558 | 0.020 |
Why?
|
| Neoplasm Staging | 2 | 2015 | 13658 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2010 | 756 | 0.020 |
Why?
|
| Alleles | 1 | 2014 | 2437 | 0.020 |
Why?
|
| Apoptosis | 1 | 2022 | 7591 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2013 | 1301 | 0.020 |
Why?
|
| Time Factors | 2 | 2015 | 12926 | 0.020 |
Why?
|
| Anthracyclines | 1 | 2010 | 331 | 0.020 |
Why?
|
| Remission Induction | 1 | 2013 | 3569 | 0.020 |
Why?
|
| Biopsy | 1 | 2015 | 3443 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2018 | 3230 | 0.020 |
Why?
|
| Chemoradiotherapy | 1 | 2013 | 1946 | 0.020 |
Why?
|
| Nervous System Diseases | 1 | 2008 | 500 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2015 | 7548 | 0.010 |
Why?
|
| Phenotype | 1 | 2015 | 6295 | 0.010 |
Why?
|
| Radiotherapy | 1 | 2010 | 1824 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2013 | 9244 | 0.010 |
Why?
|
| Mass Screening | 1 | 2008 | 1509 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2013 | 14889 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2008 | 6009 | 0.010 |
Why?
|
| United States | 1 | 2014 | 15433 | 0.010 |
Why?
|
| Prognosis | 1 | 2013 | 21713 | 0.010 |
Why?
|